EWTX Latest Headlines

Edgewise Therapeutics’ Buy Rating Reaffirmed on Encouraging EDG-7500 Data and $57 Price Target

at www.tipranks.com (Mon, 9-Nov 7:35 AM)

Edgewise Therapeutics Highlights Phase 3 HCM Plans as Sevasemten Sale Drives Q3 Net Income

Market Chameleon (Thu, 5-Nov 11:58 AM)

Edgewise readies STRATUS-HCM Phase 3 with echo-independent dosing—and a 600-patient design focused on peak VO2

Market Chameleon (Thu, 5-Nov 8:53 AM)